Oryzon Genomics S.A.
ORY
Rank in Stocks
#16262
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in... Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Share Price
$2.67
Last synced: 2026-11-09
Market Cap
$218.72M
Change (1 day)
2.66%
Change (1 year)
-21.38%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Oryzon Genomics S.A. (ORY)
Category
Healthcare
EPS for Oryzon Genomics S.A. (ORY)
EPS as of June 2026 TTM: $-0.03
According to Oryzon Genomics S.A.'s latest financial reports, its current EPS (TTM) is $-0.03. At the end of 2025 the company had an EPS of $-0.04, an increase over its 2024 EPS of $-0.06.
EPS history for Oryzon Genomics S.A. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.03 | -13.00% |
| 2025 | $-0.04 | -30.57% |
| 2024 | $-0.06 | -2.79% |
| 2023 | $-0.06 | -24.81% |
| 2022 | $-0.08 | -19.80% |
| 2021 | $-0.10 | 28.83% |
| 2020 | $-0.08 | -13.75% |
| 2019 | $-0.09 | 158.24% |
| 2018 | $-0.04 | -81.67% |
| 2017 | $-0.19 | -8.75% |
| 2016 | $-0.21 | 436.73% |
| 2015 | $-0.04 | -114.09% |
| 2014 | $0.28 | -317.59% |
| 2013 | $-0.13 | 0.00% |
| 2012 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -45,100.00% |
US
|
|
| $-7.07 | 20,216.09% |
US
|
|
| $-5.29 | 15,101.15% |
AU
|
|
| $12.88 | -37,111.78% |
BE
|
|
| $21.56 | -62,054.02% |
NL
|
Questions about Oryzon Genomics S.A.'s earnings per share (EPS)
What is Oryzon Genomics S.A.'s earnings per share (EPS)?
Oryzon Genomics S.A.'s earnings per share (EPS) over the last twelve months is $-0.03, as of Jun 2026.
What was Oryzon Genomics S.A.'s earnings per share (EPS) in 2025?
In 2025, Oryzon Genomics S.A.'s earnings per share (EPS) was $-0.04, compared with $-0.06 in 2024.
How has Oryzon Genomics S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Oryzon Genomics S.A.'s earnings per share (EPS) was highest in 2025 ($-0.04) and lowest in 2021 ($-0.10).
How does Oryzon Genomics S.A.'s earnings per share (EPS) compare with similar companies?
Oryzon Genomics S.A.'s earnings per share (EPS) ($-0.03) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.